Citi says Novartis selloff on neuromuscular trial failure looks overdone
Citi analysts said Novartis’s stock selloff following a neuromuscular drug clinical-trial failure looks overdone. They added the company reiterated its 2025-2030 outlook and noted upcoming study results could be more positive.